S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in

PJT Partners (NYSE:PJT) Raised to Buy at Zacks Investment Research

Saturday, November 21, 2020 | MarketBeat

PJT Partners (NYSE:PJT) was upgraded by Zacks Investment Research from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday, Zacks.com reports. The brokerage currently has a $77.00 price target on the financial services provider's stock. Zacks Investment Research's price objective would suggest a potential upside of 13.67% from the company's current price.

According to Zacks, "PJT Partners Inc. is a financial advisory firm. The Company offers strategic advisory, restructuring and reorganization, fund placement and funds advisory services to corporations, financial sponsors, institutional investors and governments. PJT Partners Inc. is based in NEW YORK, United States. "

Other equities analysts also recently issued research reports about the stock. JMP Securities upped their price objective on shares of PJT Partners from $70.00 to $80.00 and gave the company an "outperform" rating in a research note on Wednesday, October 28th. ValuEngine downgraded shares of PJT Partners from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, TheStreet raised shares of PJT Partners from a "c" rating to a "b-" rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of "Buy" and a consensus price target of $67.00.

Shares of PJT stock traded down $0.99 during trading hours on Friday, hitting $67.74. The company's stock had a trading volume of 231,570 shares, compared to its average volume of 166,864. The business has a fifty day moving average of $67.52 and a 200-day moving average of $57.55. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of 26.56 and a beta of 0.95. PJT Partners has a twelve month low of $23.63 and a twelve month high of $76.45.

PJT Partners (NYSE:PJT) last released its quarterly earnings results on Tuesday, October 27th. The financial services provider reported $1.36 EPS for the quarter, beating the consensus estimate of $0.80 by $0.56. The business had revenue of $297.56 million for the quarter, compared to analyst estimates of $205.99 million. PJT Partners had a net margin of 7.50% and a return on equity of 23.22%. On average, analysts anticipate that PJT Partners will post 3.34 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC purchased a new position in PJT Partners during the second quarter worth approximately $26,000. Private Advisor Group LLC purchased a new position in shares of PJT Partners in the 2nd quarter valued at $33,000. Smith Asset Management Group LP purchased a new position in shares of PJT Partners in the 3rd quarter valued at $101,000. New York State Teachers Retirement System purchased a new position in shares of PJT Partners in the 2nd quarter valued at $103,000. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in shares of PJT Partners in the 3rd quarter valued at $103,000. 68.35% of the stock is currently owned by institutional investors.

About PJT Partners

PJT Partners Inc, an investment bank, provides various strategic and shareholder advisory, restructuring and special situations, and private fund advisory and fundraising services to corporations, financial sponsors, institutional investors, and governments worldwide. It offers a range of financial advisory and transaction execution capability, including mergers and acquisitions, joint ventures, minority investments, asset swaps, divestitures, takeover defenses, corporate finance advisory, private placements, and distressed sales.

Featured Article: How to invest using market indexes

Get a free copy of the Zacks research report on PJT Partners (PJT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle

October 2, 2020, may not rank as one of those “where were you when” moments. But when news broke that the President of the United States and the First Lady tested positive for the novel coronavirus, there was certainly a sense that we were living through a historical moment (as if we already were not).

Over the following days, several biotech and pharmaceutical companies took the headlines. However, these weren’t the vaccine stocks that investors have committed to memory. These were companies that are leading the race for antiviral therapeutics.

And with a very high profile proof of concept, therapeutics may have had their moment. It’s far too early to say whether these drugs truly carry the answer. But from the outset of the pandemic, there has been a feeling that therapeutics may carry the ultimate solution to neutralizing the most severe effects of the novel coronavirus.

As you might expect, there is no shortage of companies in the therapeutic discussion. In this special presentation, we’re highlighting seven companies that you should be paying close attention to. If therapeutics nudge ahead of a vaccine, these stocks are likely to make strong upward moves.

View the "7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.